Published in J Bone Miner Res on May 01, 2011
WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med (2013) 4.52
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med (2013) 1.90
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A (2012) 1.78
Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab (2012) 1.54
Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis (2013) 1.25
LRP5 and LRP6 in development and disease. Trends Endocrinol Metab (2013) 1.21
Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res (2011) 1.05
Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis. Ann Rheum Dis (2013) 0.99
Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98
Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One (2013) 0.97
Proximal femoral density distribution and structure in relation to age and hip fracture risk in women. J Bone Miner Res (2013) 0.97
Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells (2012) 0.95
Wnt signaling and orthopedics, an overview. Acta Orthop (2011) 0.95
Anti-sclerostin antibody and mechanical loading appear to influence metaphyseal bone independently in rats. Acta Orthop (2011) 0.94
A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice. Bone Res (2013) 0.94
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis (2014) 0.94
Targeting the Wnt pathways for therapies. Mol Cell Ther (2014) 0.93
Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am (2013) 0.93
Cartilage to bone transitions in health and disease. J Endocrinol (2013) 0.93
Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res (2014) 0.93
Sclerostin Inhibition in the Management of Osteoporosis. Calcif Tissue Int (2016) 0.92
Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast. Mol Cell Biol (2015) 0.92
Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. J Bone Miner Res (2015) 0.90
Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A (2014) 0.90
A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am (2014) 0.89
The Wnt serpentine receptor Frizzled-9 regulates new bone formation in fracture healing. PLoS One (2013) 0.88
Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1-34 treatment. Bone (2014) 0.86
Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. J Cell Physiol (2012) 0.86
Acute alcohol exposure impairs fracture healing and deregulates β-catenin signaling in the fracture callus. Alcohol Clin Exp Res (2012) 0.86
Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment. PLoS One (2012) 0.86
Midkine-deficiency delays chondrogenesis during the early phase of fracture healing in mice. PLoS One (2014) 0.85
Sclerostin antibody treatment improves fracture outcomes in a Type I diabetic mouse model. Bone (2015) 0.84
A volumetric method for quantifying atherosclerosis in mice by using microCT: comparison to en face. PLoS One (2011) 0.83
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health (2015) 0.83
Biologic adjuvants for fracture healing. Arthritis Res Ther (2012) 0.82
Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J Bone Joint Surg Am (2012) 0.82
Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab (2013) 0.80
Bone anabolics in osteoporosis: Actuality and perspectives. World J Orthop (2014) 0.80
A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures. Bonekey Rep (2015) 0.80
Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model? Clin Orthop Relat Res (2015) 0.79
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats. Sci Rep (2015) 0.78
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun (2016) 0.78
Inhibitors of sclerostin: emerging concepts. Curr Opin Rheumatol (2014) 0.78
Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse. Bone (2016) 0.77
Role of Wnt signaling in fracture healing. BMB Rep (2014) 0.77
Antagonizing midkine accelerates fracture healing in mice by enhanced bone formation in the fracture callus. Br J Pharmacol (2016) 0.77
Bone repair with skeletal stem cells: rationale, progress to date and clinical application. Ther Adv Musculoskelet Dis (2016) 0.76
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. J Osteoporos (2016) 0.76
CORR Insights(®): Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model? Clin Orthop Relat Res (2016) 0.75
Transient Canonical Wnt Stimulation Enriches Human Bone Marrow Mononuclear Cell Isolates for Osteoprogenitors. Stem Cells (2015) 0.75
Inhibition of beta-catenin signaling by Pb leads to incomplete fracture healing. J Orthop Res (2014) 0.75
Novel therapeutic targets in myeloma bone disease. Br J Pharmacol (2014) 0.75
Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo. Mol Ther Nucleic Acids (2016) 0.75
Inhibition of Midkine Augments Osteoporotic Fracture Healing. PLoS One (2016) 0.75
Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis. Sci Rep (2017) 0.75
Sclerostin expression and functions beyond the osteocyte. Bone (2016) 0.75
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Osteoclast differentiation and activation. Nature (2003) 18.59
Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care (2008) 10.90
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell (2005) 7.29
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell (2010) 5.23
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
A polymer tandem solar cell with 10.6% power conversion efficiency. Nat Commun (2013) 4.48
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest (2006) 3.72
Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. J Pediatr (2007) 3.64
Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/- and Ldlr-/- mice lacking CHOP. Cell Metab (2009) 3.51
Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. Genes Dev (2010) 3.49
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell (2012) 3.30
For the bright future-bulk heterojunction polymer solar cells with power conversion efficiency of 7.4%. Adv Mater (2010) 3.24
Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology (2004) 3.14
Osteopontin expression correlates with melanoma invasion. J Invest Dermatol (2005) 3.13
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med (2007) 2.86
Different functional roles of T1R subunits in the heteromeric taste receptors. Proc Natl Acad Sci U S A (2004) 2.85
Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J Clin Invest (2009) 2.82
Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res (2011) 2.73
Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol (2010) 2.67
Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care (2008) 2.66
The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature (2005) 2.63
Four novel frameworks built by imidazole-based dicarboxylate ligands: hydro(solvo)thermal synthesis, crystal structures, and properties. Inorg Chem (2010) 2.60
Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone (2006) 2.59
Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation (2007) 2.58
A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med (2012) 2.53
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res (2010) 2.52
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation (2008) 2.44
A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes (2010) 2.39
Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol (2002) 2.35
Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol (2008) 2.33
Planar heterojunction perovskite solar cells via vapor-assisted solution process. J Am Chem Soc (2013) 2.32
Empirical likelihood analysis of the Buckley-James estimator. J Multivar Anal (2008) 2.28
A transforming metal nanocomposite with large elastic strain, low modulus, and high strength. Science (2013) 2.28
Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am J Hum Genet (2011) 2.27
Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas (2008) 2.24
Metabolic syndrome and health-related quality of life among U.S. adults. Ann Epidemiol (2008) 2.21
Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med (2009) 2.17
Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol (2006) 2.12
Defining the metabolic syndrome in children and adolescents: will the real definition please stand up? J Pediatr (2007) 2.11
Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis (2008) 2.09
Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med (2003) 2.02
Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol (2005) 2.01
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
Nebulin-deficient mice exhibit shorter thin filament lengths and reduced contractile function in skeletal muscle. J Cell Biol (2006) 2.00
Rapid skeletal turnover in a radiographic mimic of osteopetrosis. J Bone Miner Res (2014) 2.00
Transgenic malaria-resistant mosquitoes have a fitness advantage when feeding on Plasmodium-infected blood. Proc Natl Acad Sci U S A (2007) 1.99
Activation of remote meta-C-H bonds assisted by an end-on template. Nature (2012) 1.96
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum (2007) 1.95
Parallel developmental trajectories of sensation seeking and regular substance use in adolescents. Psychol Addict Behav (2003) 1.94
Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology (2007) 1.94
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood (2005) 1.94
Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J Neurosci (2010) 1.93
T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development (2005) 1.92
Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem (2004) 1.91
Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med (2013) 1.90
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Healthy lifestyle behaviors and all-cause mortality among adults in the United States. Prev Med (2012) 1.87
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Trends in obesity and abdominal obesity among hypertensive and nonhypertensive adults in the United States. Am J Hypertens (2008) 1.86
Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol (2005) 1.85
The rice HIGH-TILLERING DWARF1 encoding an ortholog of Arabidopsis MAX3 is required for negative regulation of the outgrowth of axillary buds. Plant J (2006) 1.85
Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care (2007) 1.84
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood (2002) 1.84
Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults. Circulation (2009) 1.83
Mesenchymal stem cells in immunoregulation. Immunol Cell Biol (2006) 1.82
Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother (2010) 1.82
Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev (2012) 1.82
Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care (2007) 1.78
An approach to joint analysis of longitudinal measurements and competing risks failure time data. Stat Med (2007) 1.78
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75